Julie Dechanet-Merville
Directeur/Membre du Conseil chez Lymphact - Lymphocyte Activation Technologies SA
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Diogo Remechido | M | - |
Lymphact - Lymphocyte Activation Technologies SA
 Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
| Martinho Tojo | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
| David Zeferino D'Azevedo Cristina | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
| Daniel Correia | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
| Bruno Silva-Santos | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
| Domenico Mavilio | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Portugal | 6 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Julie Dechanet-Merville
- Réseau Personnel
